



**A D R Huitema**

**Contact**

A D R Huitema

## Publications (11)

Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. *Cancer Chemother Pharmacol* 2015; 75:763-72.

Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. *Cancer Chemother Pharmacol* 2013; 73:113-24.

Jörger M, Huitema A, Illerhaus G, Ferreri A. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. *Leuk Lymphoma* 2012; 53:1867-75.

Jörger M, Huitema A, Illerhaus G, Ferreri A. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. *Leuk Lymphoma* 2011; 52:1825-7.

Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. *Cancer Chemother Pharmacol* 2011; 69:25-33.

Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non-small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. *Lung Cancer* 2011; 74:310-7.

Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. *Br J Cancer* 2010; 102:673-7.

Jörger M, Huitema A, Huizing M, Willemsse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. *British journal of clinical pharmacology* 2007; 64:622-33.

Jörger M, Huitema A, Boogerd W, van der Sande J, Schellens J, Beijnen J. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. *Basic & clinical pharmacology & toxicology* 2006; 99:133-40.

Jörger M, Huitema A, van den Bongard H, Baas P, Schornagel J, Schellens J, Beijnen J. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *British journal of clinical pharmacology* 2006; 62:71-80.

Jörger M, Huitema A, Meenhorst P, Schellens J, Beijnen J. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. *Cancer chemotherapy and pharmacology* 2005; 55:488-96.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)